Thiel-backed Com­pass adds $49M to A round, bring­ing to­tal to $132M

A Cam­bridge start­up that’s been try­ing — and fail­ing — to op­er­ate un­der the radar these past three years is now ready to step in­to the lime­light. Com­pass Ther­a­peu­tics says it’s fi­nal­ly wrapped its years-long quest to raise a Se­ries A mega-round to­tal­ing $132 mil­lion, and it’s head­ing to the clin­ic with a lead im­muno-on­col­o­gy drug.

The com­pa­ny has been col­lect­ing chunks of mon­ey for this raise over the past three years, with word leak­ing rather ear­ly in the fundrais­ing process. Re­porters have dug up fundrais­ing up­dates sev­er­al times since (in­clud­ing a piece not­ing Pe­ter Thiel was a backer), shed­ding some light on the com­pa­ny be­fore it was quite ready, Com­pass CEO Tom Schuetz tells me.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.